# Quality Review: Tumor Protease Mechanism Report

**File**: `/home/donbr/ai2026/lifesciences-deepagents/output/cqs/tumor-protease-mechanism-report.md`

**Competency Question**: "What is the pharmacological mechanism by which a tumor secretes proteases to break down the local environment and gain access to the blood?"

---

## SUMMARY VERDICT: PARTIAL

The report is well-structured, follows the correct multi-template combination (Template 6 Mechanism Elucidation + Template 1 Drug Discovery), and provides substantial sourced content with proper evidence grading. However, it fails on several protocol requirements: no disease CURIE resolution, missing LOCATE steps for several entities, no WikiPathways or PubMed tool usage, and several claims with moderate hallucination risk. Six of ten dimensions pass; four fail or partially fail.

---

## Dimension Scores

### 1. CURIE Resolution -- PARTIAL (6/10)

**Genes/Proteins -- PASS**: Four genes (MMP2, MMP9, PLAU, CTSL) are resolved to HGNC CURIEs (HGNC:7166, HGNC:7176, HGNC:9052, HGNC:2537) and their proteins to UniProt accessions (P08253, P14780, P00749, P07711). All CURIEs use the correct `HGNC:` and `UniProtKB:` prefixes per the skill conventions.

**Compounds -- PASS**: Five drugs resolved to CHEMBL CURIEs (CHEMBL:CHEMBL279785, CHEMBL:CHEMBL3833374, CHEMBL:CHEMBL76222, CHEMBL:CHEMBL4297352, CHEMBL:CHEMBL440498). Note: the CURIE format uses a redundant `CHEMBL:CHEMBL` prefix pattern (the skill specifies `CHEMBL:3137309` without the inner `CHEMBL`), but this is a minor formatting inconsistency, not a missing resolution.

**Disease -- FAIL**: No disease CURIE is resolved anywhere in the report. The competency question concerns cancer invasion/metastasis broadly, and the report mentions NSCLC, breast cancer, gastric adenocarcinoma, and oral cavity carcinoma by name but never resolves any of them to MONDO or EFO identifiers. The skill requires disease CURIEs.

**Missing entities**:
- COL18A1 (collagen XVIII) -- mentioned functionally but no HGNC CURIE resolved
- PLAUR (uPAR) -- mentioned as PLAU receptor but no HGNC CURIE
- TIMP1 -- discussed extensively in Regulatory Network but no HGNC CURIE (only STRING ID)
- PLG (plasminogen) -- mentioned as substrate but no HGNC CURIE
- LCN2 (lipocalin-2) -- discussed but no HGNC CURIE
- TGFB1 -- discussed but no HGNC CURIE
- EDN1 -- discussed but no HGNC CURIE
- MMP14 -- mentioned but no HGNC CURIE
- FN1 (fibronectin) -- mentioned in narrative but no CURIE

Total: 4 core genes resolved, 9 additional entities mentioned without CURIE resolution.

### 2. Source Attribution -- PASS (8/10)

**Sourced claims**: The report provides `[Source: tool(param)]` citations extensively. Counting across all sections:

- Resolved Entities table: 8/8 rows sourced
- Mechanism Chain table: 7/7 rows sourced
- Regulatory Network table: 5/5 rows sourced
- Growth Factor table: 2/2 rows sourced
- Drug Candidates table: 5/5 rows sourced
- Clinical Trials table: 6/6 rows sourced
- Evidence Assessment table: 15/15 claims sourced
- Narrative sections: Nearly every factual statement includes a source citation
- Gaps section: 4 explicit "no data" attributions (PLAU drugs, CTSL drugs, MMP14 drugs, ChEMBL failures)

**Unsourced claims** (minor):
- "Tumors frequently downregulate TIMP expression" (line 80) -- no tool citation, appears to be training knowledge
- "musculoskeletal syndrome (tendonitis, arthralgia)" for Marimastat (line 107) -- attributed implicitly to trial data but no specific tool citation
- "doxycycline, minocycline" as off-target MMP inhibitors (line 222) -- explicitly flagged as "not searched" but the names themselves come from training knowledge
- The claim about timing being the reason for trial failure (lines 107, 136, 200) -- interpretive synthesis, not a tool-derived fact

**Approximate ratio**: ~55 sourced claims vs ~4-5 unsourced claims. Strong overall attribution.

### 3. LOCATE-then-RETRIEVE Discipline -- PARTIAL (5/10)

**Evidence of LOCATE-then-RETRIEVE for core entities**:
- The References section (line 246) lists `hgnc_get_gene` calls for all 4 genes and `uniprot_get_protein` for all 4 proteins -- these are RETRIEVE calls.
- STRING interactions were retrieved using `string_get_interactions` with STRING IDs.
- Clinical trials used both `clinicaltrials_search_trials` (LOCATE) and `clinicaltrials_get_trial` (RETRIEVE).

**Missing LOCATE evidence**:
- No evidence of `hgnc_search_genes` (LOCATE) calls preceding the `hgnc_get_gene` (RETRIEVE) calls. The report's References section lists only `hgnc_get_gene` (RETRIEVE) with pre-known HGNC IDs. The skill requires: "NEVER skip LOCATE. NEVER use an ID you didn't get from a LOCATE call."
- No evidence of `string_search_proteins` (LOCATE) before `string_get_interactions` (RETRIEVE). STRING IDs (e.g., `9606.ENSP00000219070`) appear to have been used directly.
- No `opentargets_search_targets` (LOCATE) before `opentargets_get_associations` (RETRIEVE).
- Drug LOCATE step is unclear. The report says drugs came from `curl OpenTargets/graphql(knownDrugs)` -- this is a valid retrieval path but there is no prior LOCATE step for the drugs themselves.
- CHEMBL CURIEs appear in the drug table but no `chembl_search_compounds` (LOCATE) calls are listed in the References.

The report appears to jump directly to RETRIEVE calls using IDs that may have come from cross-references in other tool outputs (e.g., HGNC IDs from general knowledge, Ensembl IDs from HGNC cross-refs). This is a gray area -- the skill says IDs from cross-references in a RETRIEVE output are acceptable for downstream RETRIEVE calls, but the initial ANCHOR step should use LOCATE.

### 4. Disease CURIE in ENRICH Phase -- FAIL (0/10)

The skill explicitly requires (Phase 2 ENRICH): "LOCATE disease CURIE (use Ensembl ID from HGNC cross-references) ... Record disease CURIE (e.g., MONDO:0007606 for FOP) for Phase 4a/4b."

The report mentions multiple cancer types by name:
- Non-small cell lung cancer
- Breast cancer
- Gastric/GEJ adenocarcinoma
- Oral cavity carcinoma
- Small cell lung cancer

None are resolved to MONDO or EFO identifiers. The `opentargets_get_associations` calls returned disease association scores (line 64: "lung cancer (score 0.359), breast cancer (0.306)"), which would have included disease IDs (EFO or MONDO format), but these IDs are not recorded or used anywhere in the report.

This is a clear protocol violation. The disease CURIEs should have been extracted from the Open Targets association output and used to filter clinical trials in Phase 4b.

### 5. Open Targets Pagination -- PASS (7/10)

The report sources drug data from `curl OpenTargets/graphql(knownDrugs, ENSG...)` for three Ensembl IDs (ENSG00000087245 for MMP2, ENSG00000100985 for MMP9, ENSG00000122861 for PLAU).

The report explicitly acknowledges pagination issues in Tool Limitations (line 210): "The first Open Targets knownDrugs query used pagination parameters that may have caused issues (per MEMORY.md, size alone is reliable; page/index cause failures). Some drugs may have been missed if pagination was incomplete."

This self-awareness is good. The skill specifies "Use `size` parameter only ... Do NOT use `page` or `index`." The report does not confirm which pagination pattern was actually used, but it flags the risk. The fact that drugs were returned successfully for all three genes suggests the `size`-only pattern was likely followed, at least on retry.

Minor deduction: No mention of `cursor` for continuation, and no statement about whether all results were captured or truncated.

### 6. Evidence Grading -- PASS (9/10)

This dimension is executed very well.

**Claim-level grading**: 15 individual claims are graded in the Evidence Assessment table (lines 144-160). Each has:
- Base level (L1-L4)
- Applicable modifiers with justification
- Final score
- Justification text

**Overall confidence**: Median claim score = 0.75 (L3 Functional), range 0.60-0.95. Computed using median (not mean), as specified by the reporting skill.

**Grading accuracy**:
- L4 scores correctly applied to Phase 3 clinical trial claims (Marimastat, Andecaliximab)
- L3 scores for multi-database concordance claims (UniProt + HGNC + STRING)
- L2 scores for inferred relationships (plasmin-MMP activation from STRING interactions)
- Modifiers correctly applied: +0.10 for active trials, +0.05 for literature support, +0.05 for high STRING scores

**No claims below L1**: Correctly flagged ("Claims below L1 (<0.30): None").

The only minor issue: some L2 claims (e.g., "Tumor cells secrete MMP2, MMP9, PLAU, CTSL" at L2 0.60) are arguably generous -- the claim that tumor cells "constitutively secrete" these proteases is partially interpretation, not directly stated in UniProt function text. But the grading system was applied consistently.

### 7. Gain-of-Function Filter -- N/A

The competency question concerns tumor protease mechanisms in cancer broadly, not a specific gain-of-function mutation disease (like FOP with ACVR1 R206H). The report correctly does not apply a gain-of-function filter because:
- Cancer invasion via proteases is not a single-gene gain-of-function disease
- MMP inhibitors are the therapeutically appropriate drug class (inhibiting the proteases that promote invasion)
- No agonists appear in the drug candidate list

This dimension is not applicable.

### 8. Clinical Trial Validation -- PASS (8/10)

Six NCT IDs are listed in the Clinical Trials table:
- NCT00002911 -- Marked verified (checkmark), sourced to `clinicaltrials_get_trial(NCT:00002911)`
- NCT00003011 -- Marked verified, sourced to `clinicaltrials_search_trials("marimastat cancer")`
- NCT00003010 -- Marked verified, sourced to `clinicaltrials_search_trials("marimastat cancer")`
- NCT02545504 -- Marked verified, sourced to `clinicaltrials_get_trial(NCT:02545504)`
- NCT02864381 -- Marked verified, sourced to `clinicaltrials_search_trials("andecaliximab cancer")`
- NCT01803282 -- Marked verified, sourced to `clinicaltrials_search_trials("andecaliximab cancer")`

**Phase 5 VALIDATE compliance**: Two trials (NCT00002911, NCT02545504) were explicitly verified via `clinicaltrials_get_trial` (RETRIEVE step). Four trials (NCT00003011, NCT00003010, NCT02864381, NCT01803282) were sourced only from `clinicaltrials_search_trials` (LOCATE step) and are marked as verified, but the skill requires RETRIEVE verification for each NCT ID. Per the reporting skill's "Unverified NCT IDs" pitfall: "The Verified column in Clinical Trials tables must reflect Phase 5 output. If Phase 5 was not run, mark as Unverified."

Minor deduction: Four of six trials may not have gone through full RETRIEVE verification. However, the `clinicaltrials_search_trials` tool does return structured trial data, so the NCT IDs are at least confirmed to exist.

**NCT ID format note**: The report uses `NCT:00002911` (with colon) format in source citations. The skill specifies NCT IDs should be bare (`NCT03312634`) for trial nodes. This is a minor formatting inconsistency.

### 9. Completeness -- PASS (9/10)

The competency question asks: "What is the pharmacological mechanism by which a tumor secretes proteases to break down the local environment and gain access to the blood?"

The report addresses all three required components:

**Protease secretion mechanisms**: The report identifies four protease families (MMP2, MMP9, PLAU, CTSL) and describes their secretion from tumor cells (Step 1 in Mechanism Chain). The narrative explains constitutive secretion into the microenvironment with tool-sourced evidence.

**ECM breakdown**: The report describes:
- Type IV collagen cleavage by MMP2 and MMP9 (Steps 2-3)
- Fibronectin degradation by plasmin (Step 4)
- Elastin degradation by cathepsin L (narrative)
- Positive feedback loop via PLAU/plasmin activating pro-MMPs (Step 5)
- VEGF release from ECM promoting angiogenesis (Step 6)

**Intravasation (access to blood)**: Step 7 explicitly addresses tumor cell intravasation ("Access to blood vessels for metastatic dissemination"), and the narrative describes the "proteolytic highway" concept.

**Pharmacological interventions**: Five clinical-stage MMP inhibitors are identified with mechanisms, phases, and clinical outcomes. The report explains why they failed (timing, lack of stratification, off-target effects).

**Additional depth**: The report goes beyond the minimum by covering:
- Endogenous regulatory mechanisms (TIMPs, LCN2)
- Growth factor signaling (TGF-beta, endothelin)
- Therapeutic gaps (no PLAU/CTSL inhibitors)
- Future research directions

**Minor gap**: No WikiPathways search was conducted to identify canonical ECM degradation pathways (acknowledged in Tool Limitations, line 213-214). This would have strengthened pathway-level validation.

### 10. Hallucination Risk -- MEDIUM (6/10)

**Low-risk claims** (tool-grounded):
- All gene/protein identities, functions, and interactions are sourced to specific tool calls
- Drug names and phases sourced to Open Targets
- NCT IDs sourced to ClinicalTrials.gov
- STRING interaction scores explicitly cited

**Medium-risk claims** (interpretive synthesis that could embed training knowledge):
1. "Tumors frequently downregulate TIMP expression or secrete MMPs in excess of TIMP capacity" (line 80) -- No tool citation. This is a well-known biological concept but violates the grounding rule.
2. "Hydroxamate-based pan-MMP inhibitor that chelates the catalytic zinc ion in the MMP active site" (line 107) -- Mechanism of action detail (zinc chelation) is not attributed to any tool call. This level of chemical mechanism detail likely comes from training knowledge.
3. "musculoskeletal syndrome (tendonitis, arthralgia)" (line 107) -- Side effect detail without tool citation.
4. "treatment was initiated after metastasis had occurred" as reason for trial failure (lines 107, 136, 200) -- This is an interpretive claim. While plausible, no tool output is cited for this timing hypothesis.
5. "doxycycline, minocycline" as MMP off-target inhibitors (line 222) -- The report correctly flags this was "not searched," but the drug names themselves are from training knowledge.
6. "Gly-X bonds" in collagen cleavage (line 56) -- Specific biochemical detail not attributed to tool output.
7. "neutral pH" for cathepsin L activity (line 62) -- Specific condition without tool citation.

**High-risk claims**: None identified. The report does not fabricate NCT IDs, drug names, or gene identities that contradict known biology.

**Assessment**: The report generally follows the grounding rule but injects interpretive biochemical details in the narrative sections that go beyond what tool outputs would have provided. The core factual scaffold (genes, proteins, drugs, trials) is well-grounded, but the connecting narrative includes training-knowledge embellishments. Per the skill: "ALL claims in the report MUST trace to specific tool calls from Phases 1-5."

---

## Summary Scorecard

| # | Dimension | Score | Verdict |
|---|-----------|-------|---------|
| 1 | CURIE Resolution | 6/10 | PARTIAL -- 4 core genes resolved, 9 entities missing CURIEs, no disease CURIEs |
| 2 | Source Attribution | 8/10 | PASS -- ~55 sourced claims, ~4-5 unsourced, strong overall |
| 3 | LOCATE-then-RETRIEVE | 5/10 | PARTIAL -- RETRIEVE calls present, but LOCATE steps not evidenced for initial anchoring |
| 4 | Disease CURIE in ENRICH | 0/10 | FAIL -- No disease CURIEs resolved (MONDO/EFO) |
| 5 | Open Targets Pagination | 7/10 | PASS -- Self-aware about pagination risks, drugs returned successfully |
| 6 | Evidence Grading | 9/10 | PASS -- 15 claims graded, median/range computed, modifiers applied correctly |
| 7 | Gain-of-Function Filter | N/A | N/A -- Not a gain-of-function disease context |
| 8 | Clinical Trial Validation | 8/10 | PASS -- 6 NCT IDs listed, 2 fully verified via RETRIEVE, 4 from LOCATE only |
| 9 | Completeness | 9/10 | PASS -- All three mechanism components addressed, pharmacological interventions included |
| 10 | Hallucination Risk | 6/10 | MEDIUM -- Core facts grounded, but ~7 narrative claims embed training knowledge |

**Overall: PARTIAL** -- The report is substantively strong and scientifically coherent, achieving excellent scores on evidence grading, completeness, and source attribution. The primary failures are procedural: missing disease CURIE resolution (a hard requirement from the skills fix), incomplete LOCATE-then-RETRIEVE discipline for initial entity anchoring, and medium hallucination risk from interpretive narrative content that goes beyond tool outputs. Resolving these three issues would bring the report to a PASS.
